Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist.

ABSTRACT:

Background

The in-situ vaccine using CpG oligodeoxynucleotide combined with OX40 agonist antibody (CpG + OX40) has been shown to be an effective therapy activating an anti-tumor T cell response in certain settings. The roles of tumor volume, tumor model, and the addition of checkpoint blockade in the efficacy of CpG + OX40 in-situ vaccination remains unknown.

Methods

Mice bearing flank tumors (B78 melanoma or A20 lymphoma) were treated with combinations of CpG, OX40, and anti-CTLA-4. Tumor growth and survival were monitored. In vivo T cell depletion, tumor cell phenotype, and tumor infiltrating lymphocyte (TIL) studies were performed. Tumor cell sensitivity to CpG and macrophages were evaluated in vitro.

Results

As tumor volumes increased in the B78 (one-tumor) and A2

SUBMITTER: Pieper AA 

PROVIDER: S-EPMC10264285 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature